Re: BIO CEO Slides Up
in response to
by
posted on
Feb 13, 2019 10:36AM
You say:
"Said another way, the drug certainly could be playing a very strong factor in the patient group on MACE reductions which is yet another reason why they've slowed to a crawl."
That presumably would be true for patients taking Apabetalone. But not necessarily so for the placebo arm as it is the basis of this medical trial yet to be proven.
IMO...Koo